Investment Agreements in the Biotechnology Industry

97 Contracts & Agreements

Browse by Company

ACHIEVE LIFE SCIENCES, INC. (1 contract)
Actinium Pharmaceuticals, Inc. (1)
Adhera Therapeutics, Inc. (1)
ADiTx Therapeutics, Inc. (2)
Advaxis, Inc. (1)
Akebia Therapeutics, Inc. (2)
Allena Pharmaceuticals, Inc. (1)
ALNYLAM PHARMACEUTICALS, INC. (1)
Aravive, Inc. (2)
BridgeBio Pharma, Inc. (0)
CASI Pharmaceuticals, Inc. (6)
CATALYST PHARMACEUTICALS, INC. (2)
Cellular Biomedicine Group, Inc. (1)
Chardan Healthcare Acquisition 2 Corp. (2)
Cidara Therapeutics, Inc. (1)
CLEVELAND BIOLABS INC (4)
Corbus Pharmaceuticals Holdings, Inc. (1)
Cortexyme, Inc. (1)
CRISPR Therapeutics AG (1)
CYTORI THERAPEUTICS, INC. (1)
DiaMedica Therapeutics Inc. (1)
Diffusion Pharmaceuticals Inc. (3)
ENDONOVO THERAPEUTICS, INC. (1)
Environmental Impact Acquisition Corp (2)
ENZON PHARMACEUTICALS, INC. (2)
GENELUX CORP (1)
GENETHERA INC (1)
IGM Biosciences, Inc. (1)
IMMUNE PHARMACEUTICALS INC (2)
Inmune Bio, Inc. (1)
Isoray, Inc. (2)
KBL MERGER CORP. IV (3)
MeiraGTx Holdings plc (1)
MiMedx Group, Inc. (1)
NANOVIRICIDES, INC. (1)
NOVAVAX INC (1)
NTN BUZZTIME INC (1)
Ohr Pharmaceutical Inc (1)
OPGEN INC (3)
Orgenesis Inc. (1)
PDL BIOPHARMA, INC. (2)
Petra Acquisition Inc. (5)
Phio Pharmaceuticals Corp. (1)
PIERIS PHARMACEUTICALS, INC. (2)
PREMIER BIOMEDICAL INC (1)
Prevail Therapeutics Inc. (1)
Propanc Biopharma, Inc. (3)
Pyxis Oncology, Inc. (2)
Rezolute, Inc. (1)
RHYTHM PHARMACEUTICALS, INC. (1)
Rich Pharmaceuticals, Inc. (1)
Sarepta Therapeutics, Inc. (1)
SOPHIRIS BIO INC. (1)
Sorrento Therapeutics, Inc. (2)
Spero Therapeutics, Inc. (1)
SPHERIX INC (1)
Sun BioPharma, Inc. (2)
Sunshine Biopharma, Inc (1)
Tracon Pharmaceuticals, Inc. (1)
VICAL INC (1)
VITAL THERAPIES INC (2)
XOMA Corp (2)

Recent Contracts

Subscription and Investment Representation Agreement, dated August 7, 2024, by and between Pieris Pharmaceuticals, Inc. and James Geraghty (PIERIS PHARMACEUTICALS, INC., Filed With SEC on August 8, 2024)
Form of Subscription and Investment Representation Agreement, dated May 29, 2024 (Ohr Pharmaceutical Inc, Filed With SEC on May 31, 2024)
Amendment Agreement, dated May 16, 2024, by and between OpGen, Inc. and the European Investment Bank (OPGEN INC, Filed With SEC on May 22, 2024)
Subscription and Investment Representation Agreement, dated April 23, 2024, by and between Panbela Therapeutics, Inc. and Michael T. Cullen (Sun BioPharma, Inc., Filed With SEC on April 25, 2024)
Accession, Amendment and Restatement Agreement to the Finance Contract relating to the Finance Contract dated 24 July 2020, as amended from time to time, by and between the... (Cortexyme, Inc., Filed With SEC on April 1, 2024)
Investment Agreement, dated as of April 1, 2024, by and among Rhythm Pharmaceuticals, Inc., and the investors named therein (RHYTHM PHARMACEUTICALS, INC., Filed With SEC on April 1, 2024)
Investment Agreement, dated March 4, 2024 (Isoray, Inc., Filed With SEC on March 6, 2024)
Form of Investment Agreement (CRISPR Therapeutics AG, Filed With SEC on February 13, 2024)
Investment Agreement, dated as of January 8, 2024, by and among Perspective Therapeutics, Inc. and Lantheus Alpha Therapy, LLC (Isoray, Inc., Filed With SEC on January 17, 2024)
Investment Agreement, dated October 30, 2023, by and among MeiraGTx Holdings plc, Sanofi Foreign Participations B.V. and Sanofi (MeiraGTx Holdings plc, Filed With SEC on October 30, 2023)
Amendment to the Investment Agreement, dated as of July 18, 2023, between Santhera and the Company (CATALYST PHARMACEUTICALS, INC., Filed With SEC on July 21, 2023)
Subscription and Investment Representation Agreement, dated July 11, 2023, by and between Aditxt, Inc., and the purchaser signatory thereto (ADiTx Therapeutics, Inc., Filed With SEC on July 14, 2023)
Investment Agreement, dated as of June 19, 2023, by and between Santhera and the Company (certain identified information has been excluded from the exhibit because it both (i) is... (CATALYST PHARMACEUTICALS, INC., Filed With SEC on June 23, 2023)
Subscription and Investment Representation Agreement, dated April 14, 2023, by and between Panbela Therapeutics, Inc. and Michael T. Cullen (Sun BioPharma, Inc., Filed With SEC on April 18, 2023)
Investment Agreement, dated December 22, 2022, by and between the Registrant and Batiste Investments LLC (Tracon Pharmaceuticals, Inc., Filed With SEC on March 8, 2023)
Subscription and Investment Representation Agreement, dated March 3, 2023, by and between Plus Therapeutics, Inc. and the purchaser signatory thereto (CYTORI THERAPEUTICS, INC., Filed With SEC on March 3, 2023)
Subscription and Investment Representation Agreement, dated December 19, 2022, by and between Revelation Biosciences, Inc. and the purchaser signatory thereto (Petra Acquisition Inc., Filed With SEC on December 21, 2022)
Subscription and Investment Representation Agreement, dated December 1, 2022, by and between Advaxis, Inc. and the purchaser signatory thereto (Advaxis, Inc., Filed With SEC on December 2, 2022)
Subscription and Investment Representation Agreement, dated November 16, 2022, by and between Phio Pharmaceuticals Corp. and the purchaser signatory thereto (Phio Pharmaceuticals Corp., Filed With SEC on November 16, 2022)
Equity Transfer Agreement between CASI Biopharmaceuticals (Wuxi) Co., Ltd. and Shenzhen Jiadao Gongcheng Equity Investment Fund (Limited Partnership) dated September 22, 2022 (CASI Pharmaceuticals, Inc., Filed With SEC on November 14, 2022)
Subscription and Investment Representation Agreement, dated July 19, 2022, by and between Aditxt, Inc.. and the purchaser signatory thereto (ADiTx Therapeutics, Inc., Filed With SEC on July 20, 2022)
Form of Subscription and Investment Representation Agreement dated July 12, 2022 (Allena Pharmaceuticals, Inc., Filed With SEC on July 12, 2022)
Form of Umbrella Agreement Regarding Family Investments (GENELUX CORP, Filed With SEC on June 24, 2022)
Subscription and Investment Representation Agreement, dated May 25, 2022, by and between Brickell Biotech, Inc. and the purchaser signatory thereto (VICAL INC, Filed With SEC on May 25, 2022)
Investment Agreement between Akebia Therapeutics, Inc. and Vifor (International) Ltd., dated February 18, 2022 (Akebia Therapeutics, Inc., Filed With SEC on March 1, 2022)
Amendment No. 1 to Co-Development Agreement between the Registrant and BXLS V Bodyguard PCP L.P. and BXLS Family Investment Partnership V ESC L.P. dated November 23, 2021 (ALNYLAM PHARMACEUTICALS, INC., Filed With SEC on February 10, 2022)
Investment Agreement, dated as of January 3, 2022, by and among Aravive, Inc., Eshelman Ventures, LLC, and solely for purposes of Article IV and V of the Investment Agreement,... (Aravive, Inc., Filed With SEC on January 4, 2022)
Amendment to Opt-In, Investment and Additional Consideration Agreement between Pyxis Oncology, Inc. and LegoChem Biosciences, Inc., dated August 2, 2021 (Pyxis Oncology, Inc., Filed With SEC on October 1, 2021)
Opt-In, Investment and Additional Consideration Agreement between Pyxis Oncology, Inc. and LegoChem Biosciences, Inc (Pyxis Oncology, Inc., Filed With SEC on September 17, 2021)
Exit Fee Agreement, dated as of April 14, 2021 by and among Rezolute, Inc., Solar Investment Corp., as collateral agent and lender, and the other lenders named therein (Rezolute, Inc., Filed With SEC on April 19, 2021)
Capital Provision Agreement dated as of December 11, 2020 between the Company and Epps Investments LLC (PDL BIOPHARMA, INC., Filed With SEC on March 29, 2021)
Sponsor Support Agreement, dated as of March 22, 2021, by and among Chardan Healthcare Acquisition 2 Corp., Chardan Investments 2, LLC and Renovacor, Inc (Chardan Healthcare Acquisition 2 Corp., Filed With SEC on March 23, 2021)
Form of Letter Agreement among the Registrant and our officers, directors, CG Investments Inc. VI and HB Strategies LLC (Environmental Impact Acquisition Corp, Filed With SEC on January 11, 2021)
Securities Subscription Agreement, dated August 14, 2020, between the Registrant and CG Investments Inc. VI (Environmental Impact Acquisition Corp, Filed With SEC on December 21, 2020)
Tender and Support Agreement, dated December 14, 2020, by and among Eli Lilly and Company, Tyto Acquisition Corporation, OrbiMed Private Investments VI, LP (Prevail Therapeutics Inc., Filed With SEC on December 15, 2020)
Investment Agreement by and between Juventas Cell Therapy Ltd and CASI Biopharmaceuticals (WUXI) Co., Ltd. effective as of September 22, 2020 (CASI Pharmaceuticals, Inc., Filed With SEC on November 9, 2020)
Subscription Agreement, dated October 7, 2020, between the Company and Petra Investment Holdings LLC (Petra Acquisition Inc., Filed With SEC on October 13, 2020)
Investment Agreement, dated as of September 1, 2020, by and between the Registrant and Icahn Capital LP (ENZON PHARMACEUTICALS, INC., Filed With SEC on September 1, 2020)
INVESTMENTAGREEMENT BYAND BETWEEN ENZONPHARMACEUTICALS, INC. AND ICAHNCAPITAL LP DATEDAS OF SEPTEMBER 1, 2020 (ENZON PHARMACEUTICALS, INC., Filed With SEC on September 1, 2020)
Form of Subscription Agreement for Private Warrants by Petra Investment Holdings, LLC (Petra Acquisition Inc., Filed With SEC on August 26, 2020)